ctrl K

Advertisement

NewAmsterdam Pharma N.V. (NAMSW)

NASDAQ: NAMSW · Real-Time Price · USD

7.95

-0.57 (-6.69%)

At close: Apr 29, 2025, 3:28 PM

NewAmsterdam Pharma Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	45.56M	12.76M	95.91M	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a
Gross Profit	45.56M	12.76M	95.91M	n/a	n/a
Operating Income	-176.29M	-165.73M	-3.32M	-30.73M	-5.43M
Interest Income	16.88M	10.22M	268.03K	361.1K	344K
Pretax Income	-241.6M	-160.25M	-21.14M	-36.71M	-5.75M
Net Income	-241.6M	-176.94M	-21.14M	-36.71M	-5.75M
Selling & General & Admin	70.45M	29.77M	18.22M	5.27M	1.38M
Research & Development	151.41M	159.42M	81.01M	25.46M	4.04M
Other Expenses	n/a	n/a	n/a	n/a	n/a
Operating Expenses	221.85M	197.06M	116.78M	36.35M	5.4M
Interest Expense	n/a	6.8M	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	4.06M	1.6M	858.39K	11K
Cost & Expenses	221.85M	183.23M	116.78M	36.35M	5.4M
Income Tax Expense	-1K	27K	n/a	n/a	n/a
Shares Outstanding (Basic)	94.36M	82.16M	18.97M	17.75M	17.75M
Shares Outstanding (Diluted)	94.36M	82.16M	18.97M	17.75M	17.75M
EPS (Basic)	-2.56	-2.15	-1.11	-3.34	-1.15
EPS (Diluted)	-2.56	-2.15	-1.11	-3.34	-1.15
EBITDA	-241.49M	-176.86M	-3.31M	-30.73M	-5.43M
EBIT	-241.6M	-176.91M	-22.35M	n/a	n/a
Depreciation & Amortization	113K	49K	8.4K	4.39K	1K